Koru Medical Exceeds FY25 Revenue Expectations with $41.1mln, Expands into Oncology Sector.

Koru Medical (KRMD) reported FY25 revenue of $41.1 million, exceeding expectations. The company's core immunoglobulin segment and recurring patients contributed to its success. Koru Medical is expanding into oncology with a 510(k) submission for its Freedom Infusion System. The company's financial health is solid, with a strong gross margin and low debt-to-equity ratio. However, its valuation metrics suggest an overvalued stock.